Journal for ImmunoTherapy of Cancer (Nov 2021)

662 Dissecting the CD226 immune axis in the tumor microenvironment using CyTOF-based high-dimensional immunophenotyping

Jeremy Waight,
Katie Vowell,
Michael Conner,
Florence Perrin,
Paul Bojczuk,
Kenneth Hance,
Iris Roth,
Christine Donahue,
James Smothers

Affiliations

Jeremy Waight: 3GSK, King of Prussia, Pennsylvania, USA
Katie Vowell: GlaxoSmithKline, Collegeville, PA, United States
Michael Conner: GlaxoSmithKline, Collegeville, PA, United States
Florence Perrin: GlaxoSmithKline, Collegeville, PA, United States
Paul Bojczuk: GlaxoSmithKline, Collegeville, PA, United States
Kenneth Hance: GlaxoSmithKline, Collegeville, PA, United States
Iris Roth: GlaxoSmithKline, Collegeville, PA, United States
Christine Donahue: GlaxoSmithKline, Collegeville, PA, United States
James Smothers: GlaxoSmithKline, Collegeville, PA, United States

DOI: https://doi.org/10.1136/jitc-2021-SITC2021.662
Journal volume & issue: Vol. 9, no. Suppl 2

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal